이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Edesa Biotech 배당금

배당금 기준 확인 0/6

Edesa Biotech 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.9%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$2.25
3년 후 배당 수익률 예측	n/a

최근 배당금 업데이트

업데이트 없음

Recent updates

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Aug 04

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Mar 10

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Sep 30

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Dec 08

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Sep 22

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Aug 27

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Jun 18

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Apr 13

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Feb 19

Edesa Biotech receives C$14M for COVID-19 study

Feb 02

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Dec 08

Edesa Biotech EPS misses by $0.04, beats on revenue

Dec 07

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

Nov 03

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 EDSA 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: EDSA 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

Edesa Biotech 시장 대비 배당 수익률

EDSA 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (EDSA)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.9%
3년 후 애널리스트 예측 (EDSA)	n/a

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 EDSA 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 EDSA 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 EDSA 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: EDSA 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

Edesa Biotech 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech, Inc., Annual General Meeting, May 30, 2024

Price target decreased by 35% to US$24.00

Edesa Biotech, Inc. Reports Final Phase 2b Results for Dermatitis Study

Edesa Biotech, Inc. Approves Updated Phase 3 Trial Design for Edesa Biotech’S ARDS Drug

Price target decreased by 10% to US$52.33

Edesa Biotech, Inc. to Receive Up to CAD 23 Million in Funding from Federal Government

New major risk - Market cap size

New minor risk - Share price stability

Edesa Biotech (NASDAQ:EDSA) Will Have To Spend Its Cash Wisely

Edesa Biotech's Ards Drug Inhibits Inflammation from Influenza and Other Pathogens

Edesa Biotech Appoints Biotech Deal Veteran to CFO, Effective July 15, 2023

Edesa Biotech Receives Non-Compliance Notice From Nasdaq

Less than half of directors are independent

We're Keeping An Eye On Edesa Biotech's (NASDAQ:EDSA) Cash Burn Rate

Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study

Edesa Biotech, Inc. Reports Topline Phase 2B Results for Dermatology Drug

Fda Grants Fast Track to Edesa Biotech's Ards Drug Candidate

No longer forecast to breakeven

Insufficient new directors

Edesa Biotech, Inc. announced that it has received CAD 3.027754 million in funding

Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

Edesa shares jump ~11%, says monoclonal antibody cuts risk of death due to COVID by 84%

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Edesa Biotech, Inc. Reports Phase 2b Study Reaches Full Enrollment

Edesa says mid-stage trial for anti-allergic cream reached full enrollment

No longer forecast to breakeven

Edesa Biotech GAAP EPS of -$0.37 beats by $0.06

Edesa Biotech, Inc. Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

Price target decreased to US$16.33

Companies Like Edesa Biotech (NASDAQ:EDSA) Can Afford To Invest In Growth

High number of new and inexperienced directors

No longer forecast to breakeven

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Edesa Biotech, Inc., Annual General Meeting, May 18, 2022

Edesa Biotech, Inc. Appoints Jennifer M. Chao to Its Board of Directors

Edesa Biotech, Inc. Announces Peter Van Der Velden Resign from Board and Its Committees

Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech Reports Positive Phase 2 Data In Critically-Severe COVID Patients

Edesa Biotech, Inc. Announces Positive Phase 2 Data of Monoclonal Antibody in Hospitalized Covid-19 Patients

Edesa Biotech, Inc. Provides Update on Phase 2/3 Clinical Study Evaluating its Monoclonal Antibody Candidate as Single-Dose Therapy for Hospitalized COVID-19 Patients

Here's Why We're A Bit Worried About Edesa Biotech's (NASDAQ:EDSA) Cash Burn Situation

Edesa Biotech, Inc. Extends Dermatitis Study to Canada

Edesa Biotech, Inc. Completes Independent Data and Safety Monitoring Board Interim Review of COVID-19 Drug Candidate

Edesa Biotech soars 10% on favorable DSMB review of COVID-19 study

Edesa Biotech Reports Positive Interim Results in Dermatitis Trial

Is Edesa Biotech (NASDAQ:EDSA) In A Good Position To Deliver On Growth Plans?

Edesa Biotech, Inc. Completes Enrollment of More Than 50% of the Patients Planned for the Phase 2 Portion of Its Ongoing Phase 2/Phase 3 Clinical Study

Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone

Edesa Biotech, Inc., Annual General Meeting, Apr 22, 2021

Price target raised to US$17.00

Director recently sold US$58k worth of stock

Director Frank Oakes Just Sold A Bunch Of Shares In Edesa Biotech, Inc. (NASDAQ:EDSA)

Earnings beat expectations, revenue disappoints

Edesa Biotech receives C$14M for COVID-19 study

New 90-day high: US$7.48

New 90-day low: US$4.25

New 90-day low: US$4.63

Edesa Biotech (NASDAQ:EDSA) Is In A Good Position To Deliver On Growth Plans

Full year 2020 earnings released: US$0.74 loss per share

Revenue and earnings beat expectations

Edesa Biotech EPS misses by $0.04, beats on revenue

New 90-day low: US$5.40

Edesa Biotech's lead asset mid-stage dermatitis study achieves 50% enrollment

New 90-day high - US$9.45

결제의 안정성과 성장

시장 대비 배당 수익률

주주에 대한 수익 배당금

주주에 대한 현금 배당금

강력한 배당금 지급 기업 알아보기